Actively Recruiting
Rapid Research in Diagnostics Development for TB Network
Led by University of California, San Francisco · Updated on 2026-05-06
26436
Participants Needed
16
Research Sites
528 weeks
Total Duration
On this page
Sponsors
U
University of California, San Francisco
Lead Sponsor
U
University Hospital Heidelberg
Collaborating Sponsor
AI-Summary
What this Trial Is About
To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) brings together experts in TB care, technology assessment, diagnostics development, laboratory medicine, epidemiology, health economics and mathematical modeling with highly experienced clinical study sites in 10 countries.
CONDITIONS
Official Title
Rapid Research in Diagnostics Development for TB Network
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Non-hospitalized adults aged 12 years or older
- Cough lasting 2 weeks or more, or
- Presence of TB risk factors (HIV infection, self-reported close contact with TB, or history of mining work) with positive TB screening based on WHO-recommended tools
- Adults aged 12 years or older with confirmed TB and rifampin resistance for drug resistance testing
- Health workers aged 18 years or older involved in routine TB testing at clinical sites for usability assessment
You will not qualify if you...
- Completed latent or active TB treatment within the past 12 months
- Taken any anti-mycobacterial medication, including fluoroquinolones, within 2 weeks before study entry
- Living more than 20 km from the study site or unwilling to attend follow-up visits
- Unwilling to provide informed consent
- Negative or contaminated baseline sputum cultures for drug resistance testing
- Unable to provide at least two sputum samples of 3 mL each within one day of enrollment
- Health workers unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
National Center for Tuberculosis and Lung Diseases
Tbilisi, Georgia
Actively Recruiting
2
Chitoor (Christian Medical College satellite campus)
Vellore, India
Actively Recruiting
3
Christian Medical College CMC Pulmonary Outpatient Department
Vellore, India
Actively Recruiting
4
Primary care clinics (Shalom/LCC, CHAD)
Vellore, India
Actively Recruiting
5
Zankli Research Center
Abuja, Nigeria
Actively Recruiting
6
De La Salle Medical and Health Sciences Institute
Dasmariñas, Philippines
Actively Recruiting
7
Brooklyn Chest Hospital
Cape Town, South Africa
Actively Recruiting
8
Khayelitsha District Health Center
Cape Town, South Africa
Actively Recruiting
9
Kraaifontein Community Health Clinic
Cape Town, South Africa
Actively Recruiting
10
Scottsdene primary care clinic
Cape Town, South Africa
Actively Recruiting
11
Wallacedene primary care clinic
Cape Town, South Africa
Actively Recruiting
12
Kisenyi Health Center
Kampala, Uganda
Actively Recruiting
13
Mulago Outpatient Department
Kampala, Uganda
Actively Recruiting
14
Hanoi Lung Hospital, Outpatient departments
Hanoi, Vietnam
Actively Recruiting
15
National Lung Hospital, Outpatient departments
Hanoi, Vietnam
Actively Recruiting
16
Centre for Infectious Disease Research in Zambia
Lusaka, Zambia
Actively Recruiting
Research Team
A
Adithya Cattamanchi, MD
CONTACT
C
Catherine Cook, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here